Prior to Prometheus, Mr. Stenhouse spent over 25 years at AbbVie, most recently serving as Vice President ... Special consideration should be given to the potential hurdles of clinical and ...

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax ...

The team includes Bob Whitehead (Executive Chairman), a veteran in the bioscience field known for successful strategic exits and initiatives; Ramakrishna Venugopalan, PhD (Co-Founder & CEO), a former ...

On 14 November, Eli Lilly became a part of this group, after an account using its name and logo ... pharma companies, HCPs, and patients that rely on the platform for communication. Pharma giant ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

Meacham covers the Healthcare sector, focusing on stocks such as AbbVie, Pfizer, and Vertex Pharmaceuticals. Royalty Pharma has an analyst consensus of Strong Buy, with a price target consensus of $48 ...

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

Shares in AbbVie have slumped after a pair of failed ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.

Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...